- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02011724
A Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®
December 10, 2013 updated by: Organogenesis
An Open Label, Multi Center, Post Marketing Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®
The objective of the study is to demonstrate that treatment with Apligraf reduces venous leg ulcer (VLU)-related pain and improves the quality of life (QOL) of patients with a painful VLU.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Mineola, New York, United States, 11501
- Winthrop University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is a minimum of 18 years of age.
- Subject has read, understood, and signed an Institutional Review Board (IRB)-approved Informed Consent Form (ICF).
- Subject is able and willing to follow study procedures and instructions.
- Subject reports moderate VLU-related pain (defined as ≥4 based on maximum pain level over preceding 24 hours) on numeric rating scale (NRS) at both Week -2 and Day 0).
- Subject has a partial or full-thickness VLU between 1-60 cm2 and 1-36 months duration, which, in the opinion of the Investigator, has not adequately responded to conventional ulcer therapy.
- Female subject of childbearing potential has a documented negative urine pregnancy test.
- Subject (male or female) agrees to use highly effective methods of contraception for the duration of the study.
Exclusion Criteria:
- Subject has more than 1 VLU.
- Female subject who is lactating.
- Subject with significant or severe non VLU-related chronic pain which, in the Investigator's opinion, would impact subject's ability to evaluate their VLU-related pain. Subject with non-VLU-related chronic pain must be on a stable pain medication regimen and must, in the Investigator's opinion, not be anticipated to require a new pain medication for the chronic pain condition during the course of the study.
- Subject is not willing to discontinue the use of topical analgesics at the VLU (topical anesthetic is permitted for debridement).
- Subject who has arterial disease, as determined by an ankle-brachial index (ABI), of <0.65.
- Subject who has received an investigational drug, device, or biological/bioactive treatment within 30 days prior to study enrollment.
- Subject who is scheduled to have a vascular intervention on the study extremity during the study.
- Subject with a biopsy confirmed active malignancy at the VLU. Also, subject with any active malignancy not at the VLU, with the exception of squamous cell carcinoma or basal cell carcinoma.
- Subject who is currently receiving, anticipates receiving, or has received, at any time within 30 days prior to Screening visit, topical corticosteroids at the VLU.
- Subject has vasculitis, severe rheumatoid arthritis, and other collagen vascular diseases.
- Subject has signs and symptoms of wound infection, cellulitis, or osteomyelitis at the VLU.
- Subject has a VLU with an avascular wound bed.
- Subject has a VLU with exposed bone, tendon, or fascia.
- Subject has other wounds (DFU, surgical, etc.) on the same limb as the VLU.
- Subject has a known hypersensitivity to bovine collagen or to the components of the Apligraf agarose shipping medium.
- Subject previously treated with Apligraf, or any other cell or tissue-based product at the VLU within 30 days of the Screening visit.
- Subject who, in the opinion of the Investigator, has a history of alcohol or substance abuse within the previous year that could interfere with study compliance (eg, inability to attend scheduled study visits).
- Subject, who in the opinion of the Investigator, for any reason other than those listed above, will not be able to complete the study per protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apligraf
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent reduction in maximum VLU-related pain at Week 5
Time Frame: Day 0 - Week 5
|
Based on the maximum pain levels during the preceding 24 hours
|
Day 0 - Week 5
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction in maximum VLU-related pain at 48 hours following initial Apligraf application
Time Frame: Day 0 - 48 hours after Apligraf application
|
Day 0 - 48 hours after Apligraf application
|
Reduction on SF-12v2 - Pain Enhanced Health Survey at Week 5
Time Frame: Day 0 - Week 5
|
Day 0 - Week 5
|
Reduction in class and/or dose of VLU-related pain medications at Week 5
Time Frame: Day 0 - Week 5
|
Day 0 - Week 5
|
Reduction on Cardiff Wound Impact Schedule (CWIS) at Week 5
Time Frame: Day 0 - Week 5
|
Day 0 - Week 5
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in average VLU-related pain at Week 5.
Time Frame: Day 0 - Week 5
|
Day 0 - Week 5
|
|
Reduction in VLU-related pain using both maximum and average pain
Time Frame: Day 0 - Weeks 1, 2, 3, and 4
|
From baseline (Day 0) to Weeks 1, 2, 3 and 4
|
Day 0 - Weeks 1, 2, 3, and 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: William A. Marston, MD, Division of Vascular Surgery, UNC at Chapel Hill
- Principal Investigator: Scott Gorenstein, MD, Winthrop University Hospital
- Principal Investigator: David G. Armstrong, DPM, MD, PhD, Department of Surgery, University of Arizona College of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Anticipated)
January 1, 2014
Study Completion (Anticipated)
January 1, 2014
Study Registration Dates
First Submitted
December 10, 2013
First Submitted That Met QC Criteria
December 10, 2013
First Posted (Estimate)
December 13, 2013
Study Record Updates
Last Update Posted (Estimate)
December 13, 2013
Last Update Submitted That Met QC Criteria
December 10, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-VLU-003-AG
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Leg Ulcers
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
-
DeRoyal Industries, Inc.Royal College of Surgeons, Ireland; Enterprise Ireland; Tyndall National InstituteCompletedVenous Leg Ulcer | Venous Insufficiency of LegIreland
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
HealthpointCompletedVenous Leg Ulcer | Venous Stasis UlcersUnited States, Canada
-
Chang Gung Memorial HospitalRecruitingVenous Leg Ulcer | Venous Insufficiency of Leg | Venous Occlusion | Contrast Media ReactionTaiwan
-
Oneness Biotech Co., Ltd.Taipei Veterans General Hospital, Taiwan; Taipei Medical University Shuang...RecruitingVenous Leg Ulcers (VLU)Taiwan
-
University of TurkuUnknown
-
Mansoura UniversityActive, not recruitingVaricose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous RefluxEgypt
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
Macrocure Ltd.UnknownChronic Venous Leg UlcersUnited States
Clinical Trials on Apligraf
-
University Hospital, Basel, SwitzerlandOrganogenesisTerminatedEpidermolysis Bullosa | Wound HealingSwitzerland
-
OrganogenesisWithdrawn
-
OrganogenesisTerminatedEpidermolysis Bullosa Dystrophica | Epidermolysis Bullosa, JunctionalUnited States
-
OrganogenesisCompleted
-
OrganogenesisTerminated
-
OrganogenesisCompletedVenous UlcerUnited States
-
Acera Surgical, Inc.Active, not recruitingDiabetic Foot Ulcer | Venous Leg UlcerUnited States
-
Integra LifeSciences CorporationCompletedDiabetic Foot UlcerUnited States
-
U.S. Wound RegistryEnrolling by invitationVenous Stasis Ulcer | Quality of Patient CareUnited States
-
U.S. Wound RegistryUnknownDiabetic Foot Ulcers | Pressure Ulcer | Surgical Wound Dehiscence | Venous Stasis Ulcer | Chronic Non Healing WoundUnited States